Search

Your search keyword '"Hugues de Lavallade"' showing total 3 results
Start Over Author "Hugues de Lavallade" Publisher ferrata storti foundation (haematologica)
3 results on '"Hugues de Lavallade"'

1. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag

Author

Robin M. Ireland, Austin G. Kulasekararaj, Talha Munir, Judith C. W. Marsh, Dario Consonni, Wilma Barcellini, Ghulam J. Mufti, Morag Griffin, Hugues de Lavallade, Nana Benson-Quarm, Peter Hillmen, Kathryn Riley, Bruno Fattizzo, Louise Arnold, Anita Hill, and Victoria Potter

Subjects
medicine.medical_specialty, Anemia, Biopsy, Treatment outcome, Eltrombopag, MEDLINE, Benzoates, Outcome (game theory), chemistry.chemical_compound, Text mining, Bone Marrow, Internal medicine, medicine, Humans, Molecular Targeted Therapy, Aplastic anemia, Online Only Articles, Aged, Aged, 80 and over, medicine.diagnostic_test, business.industry, Anemia, Aplastic, Hematology, Prognosis, medicine.disease, Hydrazines, Treatment Outcome, chemistry, Pyrazoles, business, Biomarkers
Published
2019
Full Text
View/download PDF

2. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

Author

Ahmad Khoder, Katherine Howe, Hugues de Lavallade, Ed Kanfer, Paula Garland, Dragana Milojkovic, Jane F. Apperley, Takuya Sekine, Eva Loucaides, Nichola Cooper, Katja Hoschler, David Marin, Jiri Pavlu, Katayoun Rezvani, Donald Macdonald, Richard Szydlo, Peter Kelleher, Ian H Gabriel, Kate Stringaris, and John M. Goldman

Subjects
Adult, Male, Antibodies, Viral, Immunocompromised Host, Young Adult, Influenza A Virus, H1N1 Subtype, Immunity, Influenza, Human, Humans, Medicine, Prospective Studies, Survival rate, Aged, Aged, 80 and over, Immunity, Cellular, biology, business.industry, Vaccination, Antibody titer, Myeloid leukemia, Hematology, Hemagglutination Inhibition Tests, Middle Aged, Prognosis, medicine.disease, Survival Rate, Transplantation, Leukemia, Influenza Vaccines, Case-Control Studies, Hematologic Neoplasms, Immunology, biology.protein, Female, Original Article, Antibody, business, Stem Cell Transplantation
Abstract

Background In 2009 the declaration by the World Health Organization of a global pandemic of influenza-H1N1 virus led to a vaccination campaign to ensure protection for immunocompromised patients. The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies. Design and Methods We evaluated humoral and cellular immune responses to 2009 H1N1 vaccine in 97 adults with hematologic malignancies and compared these responses with those in 25 adult controls. Patients received two injections of vaccine 21 days apart and the controls received one dose. Antibody titers were measured using a hemagglutination-inhibition assay on days 0, 21 and 49 after injection of the first dose. Cellular immune responses to H1N1 were determined on days 0 and 49. Results By day 21 post-vaccination, protective antibody titers of 1:32 or more were seen in 100% of controls compared to 39% of patients with B-cell malignancies ( P

Published
2010
Full Text
View/download PDF

3. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

Author

Avichai Shimoni, Franck E. Nicolini, Didier Blaise, Sabine Furst, Mauricette Michallet, Izhar Hardan, Mohamad Sobh, Hugues de Lavallade, Jean El-Cheikh, Arnon Nagler, Daniela Revesz, Catherine Faucher, Mohamad Mohty, Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Oncology, Transplantation Conditioning, medicine.medical_treatment, Graft vs Host Disease, Salvage therapy, Hematopoietic stem cell transplantation, Bortezomib, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, Fatigue, Multiple myeloma, Hematopoietic Stem Cell Transplantation, Peripheral Nervous System Diseases, Hematology, Middle Aged, Boronic Acids, Combined Modality Therapy, 3. Good health, Treatment Outcome, Pyrazines, 030220 oncology & carcinogenesis, Female, Multiple Myeloma, medicine.drug, Adult, [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT], medicine.medical_specialty, Antineoplastic Agents, 03 medical and health sciences, Internal medicine, medicine, Humans, Transplantation, Homologous, Protease Inhibitors, Retrospective Studies, Salvage Therapy, business.industry, medicine.disease, Survival Analysis, Thrombocytopenia, Surgery, Transplantation, Graft-versus-host disease, Proteasome inhibitor, business, Follow-Up Studies, 030215 immunology
Abstract

We describe the results of 37 myeloma patients who received bortezomib following reduced intensity allogeneic stem cell transplantation (RIC-allo-SCT). Grade 1-2 peripheral neuropathy (35%), mild thrombocytopenia (24%) and fatigue (19%) were the most frequent adverse events, while there was no worsening of graft-vs-host disease symptoms. Twenty-seven patients (73%; 95% CI, 59-87%) achieved an objective response. With a median follow-up of 9 months from bortezomib initiation, the estimate of overall survival was 65% at 18 months while this was significantly higher (p=0.002) in the 27 patients achieving an objective response, suggesting that bortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results